Cooperation of LIM domain-binding 2 (LDB2) with EGR in the pathogenesis of schizophrenia.


Journal

EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380

Informations de publication

Date de publication:
09 04 2021
Historique:
revised: 21 01 2021
received: 22 04 2020
accepted: 25 01 2021
pubmed: 4 3 2021
medline: 26 10 2021
entrez: 3 3 2021
Statut: ppublish

Résumé

Genomic defects with large effect size can help elucidate unknown pathologic architecture of mental disorders. We previously reported on a patient with schizophrenia and a balanced translocation between chromosomes 4 and 13 and found that the breakpoint within chromosome 4 is located near the LDB2 gene. We show here that Ldb2 knockout (KO) mice displayed multiple deficits relevant to mental disorders. In particular, Ldb2 KO mice exhibited deficits in the fear-conditioning paradigm. Analysis of the amygdala suggested that dysregulation of synaptic activities controlled by the immediate early gene Arc is involved in the phenotypes. We show that LDB2 forms protein complexes with known transcription factors. Consistently, ChIP-seq analyses indicated that LDB2 binds to > 10,000 genomic sites in human neurospheres. We found that many of those sites, including the promoter region of ARC, are occupied by EGR transcription factors. Our previous study showed an association of the EGR family genes with schizophrenia. Collectively, the findings suggest that dysregulation in the gene expression controlled by the LDB2-EGR axis underlies a pathogenesis of subset of mental disorders.

Identifiants

pubmed: 33656268
doi: 10.15252/emmm.202012574
pmc: PMC8033514
doi:

Substances chimiques

LDB2 protein, human 0
LIM Domain Proteins 0
Ldb2 protein, mouse 0
Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12574

Informations de copyright

© 2021 The Authors. Published under the terms of the CC BY 4.0 license.

Références

PLoS One. 2012;7(4):e34559
pubmed: 22509321
Development. 2003 Sep;130(17):4161-75
pubmed: 12874135
Curr Opin Neurobiol. 2007 Feb;17(1):95-102
pubmed: 17258902
EBioMedicine. 2019 Jul;45:432-446
pubmed: 31255657
Am J Med Genet B Neuropsychiatr Genet. 2010 Oct 5;153B(7):1355-60
pubmed: 20687139
Science. 2018 Dec 14;362(6420):
pubmed: 30545857
Trends Genet. 2014 Jan;30(1):1-9
pubmed: 24290192
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct 1;39(1):149-55
pubmed: 22691714
Nucleic Acids Res. 2019 Jan 8;47(D1):D419-D426
pubmed: 30407594
J Clin Invest. 2017 Jan 3;127(1):215-229
pubmed: 27941246
PLoS Biol. 2007 Nov;5(11):e297
pubmed: 18001149
Genome Biol. 2006;7(10):R100
pubmed: 17076895
Biol Psychiatry. 2006 Jul 15;60(2):123-31
pubmed: 16843095
Semin Cell Dev Biol. 2018 May;77:25-32
pubmed: 28943393
Brain Struct Funct. 2015 Jul;220(4):2043-57
pubmed: 24760545
EMBO Mol Med. 2019 Dec;11(12):e10695
pubmed: 31657521
Dev Biol. 2007 Dec 15;312(2):484-500
pubmed: 17991461
Neuron. 2013 Jun 19;78(6):1024-35
pubmed: 23791196
Bioinformatics. 2013 Dec 1;29(23):3097-9
pubmed: 24008416
Bioinformatics. 2011 Jun 15;27(12):1696-7
pubmed: 21486936
Rev Neurosci. 2009;20(5-6):321-30
pubmed: 20397618
Transl Psychiatry. 2016 Nov 1;6(11):e934
pubmed: 27801899
Mol Psychiatry. 2016 Jul;21(7):885-93
pubmed: 27217147
Genes Dev. 2015 Oct 15;29(20):2108-22
pubmed: 26494787
Dev Dyn. 2003 Mar;226(3):460-9
pubmed: 12619132
J Neurochem. 2013 Mar;124(5):685-94
pubmed: 23205734
Nature. 2002 Mar 7;416(6876):99-103
pubmed: 11882901
Am J Hum Genet. 2001 Aug;69(2):428-33
pubmed: 11443544
Nucleic Acids Res. 2020 Jan 8;48(D1):D87-D92
pubmed: 31701148
Cell. 2016 Nov 3;167(4):897-914
pubmed: 27814520
Nat Genet. 1999 Aug;22(4):394-9
pubmed: 10431247
Brain Neurosci Adv. 2019 May 30;2:
pubmed: 31179400
BMC Genomics. 2014 Apr 15;15:284
pubmed: 24735413
EBioMedicine. 2020 Dec;62:103130
pubmed: 33279456
Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2815-20
pubmed: 17360599
Nat Rev Neurosci. 2007 Jun;8(6):427-37
pubmed: 17514196
Cell Struct Funct. 1995 Apr;20(2):151-6
pubmed: 7641297
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Neurotherapeutics. 2017 Jul;14(3):623-629
pubmed: 28664299
Methods Find Exp Clin Pharmacol. 2007 May;29(4):291-301
pubmed: 17609743
Hum Genome Var. 2020 Sep 29;7:31
pubmed: 33082982
EMBO Rep. 2003 Dec;4(12):1132-7
pubmed: 14647207
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
Development. 2003 Feb;130(3):495-505
pubmed: 12490556
Schizophr Res. 2020 Mar;217:52-59
pubmed: 30765249
Genes Dev. 2001 Sep 1;15(17):2215-28
pubmed: 11544179
Development. 2018 Apr 30;145(9):
pubmed: 29650591
Cell Biol Toxicol. 2018 Oct;34(5):381-404
pubmed: 29568981
Schizophr Res. 2020 Mar;217:4-12
pubmed: 31780348
Nat Genet. 2019 May;51(5):793-803
pubmed: 31043756
Neuropsychopharmacology. 2018 Nov;43(12):2487-2496
pubmed: 29941977
J Biol Chem. 2014 Apr 11;289(15):10785-10796
pubmed: 24554717
Brain Res. 2017 Jan 15;1655:270-276
pubmed: 26801829
Hum Mol Genet. 2014 Dec 15;23(24):6495-511
pubmed: 25027319
Neuron. 2007 May 3;54(3):387-402
pubmed: 17481393
Psychiatry Clin Neurosci. 2004 Jun;58(3):333-7
pubmed: 15149303
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
J Physiol. 2008 May 15;586(10):2539-50
pubmed: 18372311
J Biochem. 2006 Jul;140(1):105-19
pubmed: 16815859
eNeuro. 2019 Mar 12;6(1):
pubmed: 30873428
Neurosci Lett. 2015 Aug 5;601:46-53
pubmed: 25478958
Radiat Res. 2017 Nov;188(5):532-551
pubmed: 28945526
Mol Cell. 2003 Nov;12(5):1187-200
pubmed: 14636577
Sci Rep. 2017 Jul 10;7(1):4957
pubmed: 28694486
Transl Psychiatry. 2017 Sep 5;7(9):e1229
pubmed: 28872641

Auteurs

Tetsuo Ohnishi (T)

Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Wako, Japan.

Yuji Kiyama (Y)

Division of Neuronal Network, Institute of Medical Science, the University of Tokyo, Tokyo, Japan.
Laboratory of Biochemistry and Molecular Biology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Fumiko Arima-Yoshida (F)

Division of Neuronal Network, Institute of Medical Science, the University of Tokyo, Tokyo, Japan.
Institute of Clinical Medicine and Research, The Jikei University School of Medicine, Tokyo, Japan.

Mitsutaka Kadota (M)

Laboratory for Phyloinformatics, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.

Tomoe Ichikawa (T)

Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Sciences, Shizuoka, Japan.
Department of Infection Control Science, Meiji Pharmaceutical University, Kiyose, Japan.

Kazuyuki Yamada (K)

School of Management, Shizuoka Sangyo University, Iwata, Japan.
RIKEN, Wako, Japan.

Akiko Watanabe (A)

Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Wako, Japan.

Hisako Ohba (H)

Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Wako, Japan.

Kaori Tanaka (K)

Laboratory for Phyloinformatics, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.

Akihiro Nakaya (A)

Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Wako, Japan.
Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Yasue Horiuchi (Y)

Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Sciences, Shizuoka, Japan.

Yoshimi Iwayama (Y)

Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Wako, Japan.
RIKEN, Wako, Japan.

Manabu Toyoshima (M)

Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Wako, Japan.

Itone Ogawa (I)

Division of Neuronal Network, Institute of Medical Science, the University of Tokyo, Tokyo, Japan.

Chie Shimamoto-Mitsuyama (C)

Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Wako, Japan.

Motoko Maekawa (M)

Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Wako, Japan.

Shabeesh Balan (S)

Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Wako, Japan.

Makoto Arai (M)

Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Sciences, Shizuoka, Japan.

Mitsuhiro Miyashita (M)

Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Sciences, Shizuoka, Japan.

Kazuya Toriumi (K)

Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Sciences, Shizuoka, Japan.

Yayoi Nozaki (Y)

Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Wako, Japan.

Rumi Kurokawa (R)

RIKEN, Wako, Japan.

Kazuhiro Suzuki (K)

Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Sciences, Shizuoka, Japan.

Akane Yoshikawa (A)

Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Sciences, Shizuoka, Japan.

Tomoko Toyota (T)

Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Wako, Japan.

Toshihiko Hosoya (T)

RIKEN, Wako, Japan.
Biomedical Business Center, RICOH Company, LTD, Kawasaki, Japan.

Hiroyuki Okuno (H)

Laboratory of Biochemistry and Molecular Biology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Haruhiko Bito (H)

Department of Neurochemistry, the University of Tokyo, Graduate School of Medicine, Tokyo, Japan.

Masanari Itokawa (M)

Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Sciences, Shizuoka, Japan.

Shigehiro Kuraku (S)

Laboratory for Phyloinformatics, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.

Toshiya Manabe (T)

Division of Neuronal Network, Institute of Medical Science, the University of Tokyo, Tokyo, Japan.

Takeo Yoshikawa (T)

Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Wako, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH